{"gene":"PF3D7_1014400","run_date":"2026-09-08T12:51:28","timeline":{"discoveries":[{"year":1996,"finding":"MRK (PF3D7_1014400, referred to as Pfmrk in the abstract) is a single-copy gene on chromosome 10 encoding a 324-amino-acid CDK-like protein with highest similarity to human CDK7/MO15, containing two unique inserts (one of 5 amino acids before the cyclin-binding motif, one of 13 amino acids within the T-loop equivalent region); its 2500-nucleotide transcript is expressed predominantly in sexual blood stages (gametocytes).","method":"Gene cloning, sequence analysis, Southern blotting of genomic DNA, chromosomal separation, Northern blot / stage-specific expression analysis","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct molecular characterization (cloning, Southern, chromosomal localization, stage-specific expression), single lab, multiple orthogonal methods","pmids":["8944769"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2000,"finding":"Recombinant MRK (PF3D7_1014400) expressed in E. coli exhibits histone H1 kinase activity and undergoes autophosphorylation in vitro; human cyclin H forms a stable complex with MRK and stimulates its kinase activity; olomoucine and roscovitine fail to inhibit MRK kinase activity.","method":"Recombinant protein expression (6xHis-tagged in E. coli), in vitro histone H1 kinase assay, autophosphorylation assay, complex formation assay, CDK inhibitor inhibition assay","journal":"Molecular and biochemical parasitology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple assays (kinase activity, autophosphorylation, cyclin complex formation, inhibitor profiling), single lab but multiple orthogonal methods","pmids":["10717301"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2001,"finding":"Recombinant MRK (PF3D7_1014400) is inhibited by heterologous human p21(CIP1) in vitro; human p16(INK4) fails to inhibit MRK.","method":"In vitro kinase inhibition assay with recombinant proteins","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro biochemical assay, single lab, single method","pmids":["11700040"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2006,"finding":"PfMAT1 (identified as an effector protein) stimulates MRK (PF3D7_1014400) kinase activity in a cyclin-dependent manner; PfMAT1 addition stimulates RNA polymerase II CTD phosphorylation by MRK but does not enable MRK to phosphorylate PfPK5, suggesting MRK functions as a CTD kinase rather than a CAK; active-site mutations S138K and F143L in MRK yield a 4–10-fold increase in kinase activity independently of cyclin or PfMAT1; MRK autophosphorylation is unaffected by cyclin or PfMAT1.","method":"In vitro kinase assays with recombinant proteins, active-site mutagenesis (S138K and F143L), CTD phosphorylation assay, substrate specificity assay","journal":"Molecular and biochemical parasitology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutagenesis and multiple substrate assays, single lab but multiple orthogonal methods","pmids":["16737745"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2010,"finding":"MRK (PF3D7_1014400) physically interacts with PfMAT1 as shown by co-immunoprecipitation; the C-terminal domain of PfMAT1 is identified as the MRK activator domain; MRK and PfMAT1 co-localize to the parasite nucleus as demonstrated by immunofluorescence of GFP- and RFP-tagged versions; a bacterial two-hybrid screen identified DNA replication proteins PfRFC-5 and PfMCM6 as interactors with MRK; PfRFC-5 and PfMCM6 are substrates of MRK-mediated phosphorylation; PfMAT1 confers substrate specificity to the MRK kinase complex.","method":"Co-immunoprecipitation, GFP/RFP immunofluorescence, bacterial two-hybrid screen of P. falciparum cDNA library, in vitro phosphorylation assay","journal":"Molecular and biochemical parasitology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal co-IP, live-cell fluorescence localization, two-hybrid interaction screen, and in vitro phosphorylation assays, single lab but multiple orthogonal methods","pmids":["20332005"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2011,"finding":"Kinome-wide reverse genetics identified MRK (PF3D7_1014400) as among 36 parasite kinases likely essential for erythrocytic schizogony; PfCLK3 (a separate kinase) phosphorylation at Y526 is essential for full kinase activity (this finding is about PfCLK3, not MRK — not attributed to MRK).","method":"Kinome-wide reverse genetics screen","journal":"Nature communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — genome-wide reverse genetics screen, MRK identified as essential among 36 kinases but no specific mechanistic detail established for MRK alone, single study","pmids":["22127061"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]}],"current_model":"MRK (PF3D7_1014400) is a P. falciparum CDK7/MO15-related cyclin-dependent kinase that localizes to the parasite nucleus, possesses intrinsic histone H1 kinase activity and autophosphorylation activity, is activated by human cyclin H and by its endogenous effector PfMAT1 (whose C-terminal domain mediates activation) in a cyclin-dependent manner, phosphorylates RNA polymerase II CTD but not PfPK5 (suggesting a role as a CTD kinase rather than a CAK), and phosphorylates the DNA replication proteins PfRFC-5 and PfMCM6 with PfMAT1 conferring substrate specificity; gain-of-function active-site mutations (S138K, F143L) render MRK constitutively active, and the kinase is likely essential for erythrocytic schizogony."},"narrative":{"mechanistic_narrative":"MRK (PF3D7_1014400) is a Plasmodium falciparum cyclin-dependent kinase most similar to human CDK7/MO15 that functions within the parasite nucleus to phosphorylate RNA polymerase II and DNA replication substrates [PMID:8944769, PMID:20332005]. As a recombinant enzyme it displays intrinsic histone H1 kinase and autophosphorylation activity, forms a stable complex with human cyclin H that stimulates its activity, and is refractory to the classical CDK inhibitors olomoucine and roscovitine while being inhibited by human p21(CIP1) but not p16(INK4) [PMID:10717301, PMID:11700040]. Its endogenous activator is PfMAT1, whose C-terminal domain physically associates with and stimulates MRK in a cyclin-dependent manner and confers substrate specificity to the kinase complex [PMID:16737745, PMID:20332005]. Functionally, MRK phosphorylates the RNA polymerase II CTD but does not phosphorylate PfPK5, distinguishing it as a CTD kinase rather than a CDK-activating kinase, and phosphorylates the DNA replication proteins PfRFC-5 and PfMCM6 identified as interactors [PMID:16737745, PMID:20332005]. Active-site mutations S138K and F143L render MRK constitutively active independently of cyclin or PfMAT1 [PMID:16737745]. The kinase is transcribed predominantly in gametocytes yet was identified as likely essential for erythrocytic schizogony [PMID:8944769, PMID:22127061].","teleology":[{"year":1996,"claim":"Establishing that P. falciparum encodes a CDK7/MO15-like kinase defined MRK as a candidate cell-cycle/transcription regulator and set its sequence and expression baseline.","evidence":"Gene cloning, sequence analysis, Southern blotting, chromosomal separation, and stage-specific Northern blot","pmids":["8944769"],"confidence":"Medium","gaps":["No functional or enzymatic activity demonstrated","Role of the two unique inserts near the cyclin-binding and T-loop regions unknown","Predominant gametocyte transcription not reconciled with a proposed schizogony role"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2000,"claim":"Reconstituting recombinant MRK demonstrated it is a bona fide kinase whose activity depends on a cyclin partner, answering whether the CDK7-like sequence corresponds to an active enzyme.","evidence":"Recombinant 6xHis MRK in E. coli with histone H1 kinase, autophosphorylation, cyclin H complex formation, and inhibitor-profiling assays","pmids":["10717301"],"confidence":"High","gaps":["Endogenous parasite cyclin partner not identified","Physiological substrates beyond histone H1 unknown","Resistance to olomoucine/roscovitine unexplained mechanistically"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2001,"claim":"Differential inhibition by human p21(CIP1) versus p16(INK4) provided a pharmacological handle distinguishing MRK regulation from other CDK classes.","evidence":"In vitro kinase inhibition assays with recombinant human CDK inhibitors","pmids":["11700040"],"confidence":"Medium","gaps":["No endogenous parasite inhibitor identified","Single in vitro method without cellular validation"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2006,"claim":"Identifying PfMAT1 as an activator and testing substrate preference resolved whether MRK acts as a CTD kinase or a CDK-activating kinase.","evidence":"In vitro kinase assays with PfMAT1, RNA Pol II CTD and PfPK5 substrate assays, and S138K/F143L active-site mutagenesis","pmids":["16737745"],"confidence":"High","gaps":["In vivo relevance of CTD phosphorylation not shown","Structural basis of constitutive activation by S138K/F143L unresolved"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2010,"claim":"Mapping the MRK–PfMAT1 interaction, nuclear co-localization, and identifying PfRFC-5 and PfMCM6 as substrates connected MRK to both transcription and DNA replication machinery.","evidence":"Co-immunoprecipitation, GFP/RFP immunofluorescence, bacterial two-hybrid screen of a P. falciparum cDNA library, and in vitro phosphorylation assays","pmids":["20332005"],"confidence":"High","gaps":["Physiological consequence of PfRFC-5/PfMCM6 phosphorylation in replication not demonstrated","Two-hybrid interactions not all validated in parasites","Full endogenous activating cyclin still undefined"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2011,"claim":"A kinome-wide screen placed MRK among kinases essential for asexual blood-stage growth, elevating its interest as a drug target.","evidence":"Kinome-wide reverse genetics screen scoring genes for essentiality in erythrocytic schizogony","pmids":["22127061"],"confidence":"Low","gaps":["Essentiality inferred from screen, not a dedicated conditional knockout of MRK","No mechanistic link between the essential phenotype and MRK's CTD/replication substrate activities"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":null,"claim":"The endogenous parasite cyclin that activates MRK in vivo, and how its CTD-kinase and replication-substrate activities integrate to make it essential, remain undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No native activating cyclin identified for MRK","No conditional-knockout mechanistic dissection of the essential phenotype","No structure of the MRK–PfMAT1 complex"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]}],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[],"complexes":["MRK–PfMAT1 kinase complex","MRK–human cyclin H complex (in vitro)"],"partners":["PFMAT1 (ENDOGENOUS ACTIVATOR; C-TERMINAL ACTIVATOR DOMAIN)","HUMAN CYCLIN H (HETEROLOGOUS ACTIVATOR IN VITRO)","PFRFC-5 (INTERACTOR AND SUBSTRATE)","PFMCM6 (INTERACTOR AND SUBSTRATE)","RNA POLYMERASE II CTD (SUBSTRATE)","HUMAN P21(CIP1) (HETEROLOGOUS INHIBITOR IN VITRO)"],"other_free_text":["324-amino-acid CDK7/MO15-related kinase with two unique inserts near the cyclin-binding and T-loop regions [#0]","Transcript expressed predominantly in gametocytes despite inferred asexual-stage essentiality [#0, #5]","Gain-of-function active-site mutations S138K and F143L confer cyclin/PfMAT1-independent constitutive activity [#3]","Not inhibited by olomoucine or roscovitine; inhibited by human p21(CIP1) but not p16(INK4) in vitro [#1, #2]"]}},"prefetch_data":{},"corpus_meta":[{"pmid":"22127061","id":"PMC_22127061","title":"Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum.","date":"2011","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/22127061","citation_count":288,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"22047078","id":"PMC_22047078","title":"Structural and evolutionary divergence of eukaryotic protein kinases in Apicomplexa.","date":"2011","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/22047078","citation_count":70,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"8944769","id":"PMC_8944769","title":"Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.","date":"1996","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8944769","citation_count":64,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["MO15"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"15481979","id":"PMC_15481979","title":"A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.","date":"2004","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15481979","citation_count":40,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"10717301","id":"PMC_10717301","title":"Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum.","date":"2000","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/10717301","citation_count":34,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"16737745","id":"PMC_16737745","title":"Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase.","date":"2006","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/16737745","citation_count":29,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"20332005","id":"PMC_20332005","title":"The malarial CDK Pfmrk and its effector PfMAT1 phosphorylate DNA replication proteins and co-localize in the nucleus.","date":"2010","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/20332005","citation_count":26,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"11700040","id":"PMC_11700040","title":"Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11700040","citation_count":22,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"17588749","id":"PMC_17588749","title":"Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.","date":"2007","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/17588749","citation_count":18,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6828,"output_tokens":2030,"usd":0.025467,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":7165,"output_tokens":3072,"usd":0.056313,"stage2_stop_reason":"end_turn"},"total_usd":0.08178,"stage1_batch_id":"msgbatch_01DisAaTypwmC8QwdMBuePHo","stage2_batch_id":"msgbatch_0184zxZTqxiEfdYYfPMfkqjb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"MRK (PF3D7_1014400, referred to as Pfmrk in the abstract) is a single-copy gene on chromosome 10 encoding a 324-amino-acid CDK-like protein with highest similarity to human CDK7/MO15, containing two unique inserts (one of 5 amino acids before the cyclin-binding motif, one of 13 amino acids within the T-loop equivalent region); its 2500-nucleotide transcript is expressed predominantly in sexual blood stages (gametocytes).\",\n      \"method\": \"Gene cloning, sequence analysis, Southern blotting of genomic DNA, chromosomal separation, Northern blot / stage-specific expression analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct molecular characterization (cloning, Southern, chromosomal localization, stage-specific expression), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"8944769\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Recombinant MRK (PF3D7_1014400) expressed in E. coli exhibits histone H1 kinase activity and undergoes autophosphorylation in vitro; human cyclin H forms a stable complex with MRK and stimulates its kinase activity; olomoucine and roscovitine fail to inhibit MRK kinase activity.\",\n      \"method\": \"Recombinant protein expression (6xHis-tagged in E. coli), in vitro histone H1 kinase assay, autophosphorylation assay, complex formation assay, CDK inhibitor inhibition assay\",\n      \"journal\": \"Molecular and biochemical parasitology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple assays (kinase activity, autophosphorylation, cyclin complex formation, inhibitor profiling), single lab but multiple orthogonal methods\",\n      \"pmids\": [\"10717301\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Recombinant MRK (PF3D7_1014400) is inhibited by heterologous human p21(CIP1) in vitro; human p16(INK4) fails to inhibit MRK.\",\n      \"method\": \"In vitro kinase inhibition assay with recombinant proteins\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro biochemical assay, single lab, single method\",\n      \"pmids\": [\"11700040\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PfMAT1 (identified as an effector protein) stimulates MRK (PF3D7_1014400) kinase activity in a cyclin-dependent manner; PfMAT1 addition stimulates RNA polymerase II CTD phosphorylation by MRK but does not enable MRK to phosphorylate PfPK5, suggesting MRK functions as a CTD kinase rather than a CAK; active-site mutations S138K and F143L in MRK yield a 4–10-fold increase in kinase activity independently of cyclin or PfMAT1; MRK autophosphorylation is unaffected by cyclin or PfMAT1.\",\n      \"method\": \"In vitro kinase assays with recombinant proteins, active-site mutagenesis (S138K and F143L), CTD phosphorylation assay, substrate specificity assay\",\n      \"journal\": \"Molecular and biochemical parasitology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutagenesis and multiple substrate assays, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16737745\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MRK (PF3D7_1014400) physically interacts with PfMAT1 as shown by co-immunoprecipitation; the C-terminal domain of PfMAT1 is identified as the MRK activator domain; MRK and PfMAT1 co-localize to the parasite nucleus as demonstrated by immunofluorescence of GFP- and RFP-tagged versions; a bacterial two-hybrid screen identified DNA replication proteins PfRFC-5 and PfMCM6 as interactors with MRK; PfRFC-5 and PfMCM6 are substrates of MRK-mediated phosphorylation; PfMAT1 confers substrate specificity to the MRK kinase complex.\",\n      \"method\": \"Co-immunoprecipitation, GFP/RFP immunofluorescence, bacterial two-hybrid screen of P. falciparum cDNA library, in vitro phosphorylation assay\",\n      \"journal\": \"Molecular and biochemical parasitology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal co-IP, live-cell fluorescence localization, two-hybrid interaction screen, and in vitro phosphorylation assays, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"20332005\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Kinome-wide reverse genetics identified MRK (PF3D7_1014400) as among 36 parasite kinases likely essential for erythrocytic schizogony; PfCLK3 (a separate kinase) phosphorylation at Y526 is essential for full kinase activity (this finding is about PfCLK3, not MRK — not attributed to MRK).\",\n      \"method\": \"Kinome-wide reverse genetics screen\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — genome-wide reverse genetics screen, MRK identified as essential among 36 kinases but no specific mechanistic detail established for MRK alone, single study\",\n      \"pmids\": [\"22127061\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    }\n  ],\n  \"current_model\": \"MRK (PF3D7_1014400) is a P. falciparum CDK7/MO15-related cyclin-dependent kinase that localizes to the parasite nucleus, possesses intrinsic histone H1 kinase activity and autophosphorylation activity, is activated by human cyclin H and by its endogenous effector PfMAT1 (whose C-terminal domain mediates activation) in a cyclin-dependent manner, phosphorylates RNA polymerase II CTD but not PfPK5 (suggesting a role as a CTD kinase rather than a CAK), and phosphorylates the DNA replication proteins PfRFC-5 and PfMCM6 with PfMAT1 conferring substrate specificity; gain-of-function active-site mutations (S138K, F143L) render MRK constitutively active, and the kinase is likely essential for erythrocytic schizogony.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MRK (PF3D7_1014400) is a Plasmodium falciparum cyclin-dependent kinase most similar to human CDK7/MO15 that functions within the parasite nucleus to phosphorylate RNA polymerase II and DNA replication substrates [#0, #4]. As a recombinant enzyme it displays intrinsic histone H1 kinase and autophosphorylation activity, forms a stable complex with human cyclin H that stimulates its activity, and is refractory to the classical CDK inhibitors olomoucine and roscovitine while being inhibited by human p21(CIP1) but not p16(INK4) [#1, #2]. Its endogenous activator is PfMAT1, whose C-terminal domain physically associates with and stimulates MRK in a cyclin-dependent manner and confers substrate specificity to the kinase complex [#3, #4]. Functionally, MRK phosphorylates the RNA polymerase II CTD but does not phosphorylate PfPK5, distinguishing it as a CTD kinase rather than a CDK-activating kinase, and phosphorylates the DNA replication proteins PfRFC-5 and PfMCM6 identified as interactors [#3, #4]. Active-site mutations S138K and F143L render MRK constitutively active independently of cyclin or PfMAT1 [#3]. The kinase is transcribed predominantly in gametocytes yet was identified as likely essential for erythrocytic schizogony [#0, #5].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing that P. falciparum encodes a CDK7/MO15-like kinase defined MRK as a candidate cell-cycle/transcription regulator and set its sequence and expression baseline.\",\n      \"evidence\": \"Gene cloning, sequence analysis, Southern blotting, chromosomal separation, and stage-specific Northern blot\",\n      \"pmids\": [\"8944769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional or enzymatic activity demonstrated\", \"Role of the two unique inserts near the cyclin-binding and T-loop regions unknown\", \"Predominant gametocyte transcription not reconciled with a proposed schizogony role\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Reconstituting recombinant MRK demonstrated it is a bona fide kinase whose activity depends on a cyclin partner, answering whether the CDK7-like sequence corresponds to an active enzyme.\",\n      \"evidence\": \"Recombinant 6xHis MRK in E. coli with histone H1 kinase, autophosphorylation, cyclin H complex formation, and inhibitor-profiling assays\",\n      \"pmids\": [\"10717301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous parasite cyclin partner not identified\", \"Physiological substrates beyond histone H1 unknown\", \"Resistance to olomoucine/roscovitine unexplained mechanistically\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Differential inhibition by human p21(CIP1) versus p16(INK4) provided a pharmacological handle distinguishing MRK regulation from other CDK classes.\",\n      \"evidence\": \"In vitro kinase inhibition assays with recombinant human CDK inhibitors\",\n      \"pmids\": [\"11700040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No endogenous parasite inhibitor identified\", \"Single in vitro method without cellular validation\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying PfMAT1 as an activator and testing substrate preference resolved whether MRK acts as a CTD kinase or a CDK-activating kinase.\",\n      \"evidence\": \"In vitro kinase assays with PfMAT1, RNA Pol II CTD and PfPK5 substrate assays, and S138K/F143L active-site mutagenesis\",\n      \"pmids\": [\"16737745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of CTD phosphorylation not shown\", \"Structural basis of constitutive activation by S138K/F143L unresolved\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapping the MRK–PfMAT1 interaction, nuclear co-localization, and identifying PfRFC-5 and PfMCM6 as substrates connected MRK to both transcription and DNA replication machinery.\",\n      \"evidence\": \"Co-immunoprecipitation, GFP/RFP immunofluorescence, bacterial two-hybrid screen of a P. falciparum cDNA library, and in vitro phosphorylation assays\",\n      \"pmids\": [\"20332005\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of PfRFC-5/PfMCM6 phosphorylation in replication not demonstrated\", \"Two-hybrid interactions not all validated in parasites\", \"Full endogenous activating cyclin still undefined\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"A kinome-wide screen placed MRK among kinases essential for asexual blood-stage growth, elevating its interest as a drug target.\",\n      \"evidence\": \"Kinome-wide reverse genetics screen scoring genes for essentiality in erythrocytic schizogony\",\n      \"pmids\": [\"22127061\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Essentiality inferred from screen, not a dedicated conditional knockout of MRK\", \"No mechanistic link between the essential phenotype and MRK's CTD/replication substrate activities\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous parasite cyclin that activates MRK in vivo, and how its CTD-kinase and replication-substrate activities integrate to make it essential, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No native activating cyclin identified for MRK\", \"No conditional-knockout mechanistic dissection of the essential phenotype\", \"No structure of the MRK–PfMAT1 complex\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0004693\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0004674\", \"supporting_discovery_ids\": [1, 3, 4]},\n      {\"term_id\": \"GO:0046777\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0008353\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0006366\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0006260\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0051301\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [\n      \"MRK–PfMAT1 kinase complex\",\n      \"MRK–human cyclin H complex (in vitro)\"\n    ],\n    \"partners\": [\n      \"PfMAT1 (endogenous activator; C-terminal activator domain)\",\n      \"human cyclin H (heterologous activator in vitro)\",\n      \"PfRFC-5 (interactor and substrate)\",\n      \"PfMCM6 (interactor and substrate)\",\n      \"RNA polymerase II CTD (substrate)\",\n      \"human p21(CIP1) (heterologous inhibitor in vitro)\"\n    ],\n    \"other_free_text\": [\n      \"324-amino-acid CDK7/MO15-related kinase with two unique inserts near the cyclin-binding and T-loop regions [#0]\",\n      \"Transcript expressed predominantly in gametocytes despite inferred asexual-stage essentiality [#0, #5]\",\n      \"Gain-of-function active-site mutations S138K and F143L confer cyclin/PfMAT1-independent constitutive activity [#3]\",\n      \"Not inhibited by olomoucine or roscovitine; inhibited by human p21(CIP1) but not p16(INK4) in vitro [#1, #2]\"\n    ]\n  }\n}","audit_flag":null,"strains":[{"strain":"Pf3D7","gene_id":"PF3D7_1014400","name":null,"product":"MO15-related protein kinase","uniprot_acc":null,"chromosome":null,"start_pos":null},{"strain":"PbANKA","gene_id":"PBANKA_1212800","name":null,"product":"MO15-related protein kinase","uniprot_acc":null,"chromosome":null,"start_pos":null},{"strain":"PkH","gene_id":"PKNH_0814500","name":null,"product":"MO15-related protein kinase","uniprot_acc":null,"chromosome":null,"start_pos":null}],"gene_symbol":"MRK","evaluation":null}